Sonoma Pharmaceuticals (NASDAQ:SNOA) is a specialty company focused on developing and offering unique treatments for dermatological conditions and advanced tissue care. It harnesses innovative technology to create products that aim to treat infections, enhance healing, and reduce healthcare costs, tackling issues from chronic and acute wounds to various skin disorders. Sonoma's portfolio includes antimicrobial solutions based on hypochlorous acid, designed to support patients across various stages of care. The company's objective is to improve patient outcomes through high-quality, safe, and effective treatments, driving innovation in skin and wound care. With a commitment to research and development, Sonoma works on expanding its reach and impact, actively seeking to address unmet medical needs in the dermatological space.